HC Wainwright Issues Optimistic Outlook for SPRB Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Spruce Biosciences in a note issued to investors on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($8.92) per share for the quarter, up from their previous estimate of ($10.46). HC Wainwright currently has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q2 2026 earnings at ($8.20) EPS, Q3 2026 earnings at ($8.08) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($32.66) EPS and FY2027 earnings at ($14.12) EPS.

Spruce Biosciences (NASDAQ:SPRB) last released its quarterly earnings data on Thursday, March 12th. The company reported ($9.58) earnings per share for the quarter, missing the consensus estimate of ($9.16) by ($0.42).

Several other brokerages have also issued reports on SPRB. Oppenheimer assumed coverage on shares of Spruce Biosciences in a report on Tuesday, December 23rd. They set an “outperform” rating and a $283.00 price objective on the stock. Citizens Jmp reduced their price target on Spruce Biosciences from $180.00 to $170.00 and set a “market outperform” rating for the company in a research report on Tuesday. Wall Street Zen cut Spruce Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 27th. Leerink Partners upgraded Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Spruce Biosciences in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $170.10.

Spruce Biosciences Stock Performance

NASDAQ:SPRB opened at $64.18 on Thursday. The firm has a 50-day simple moving average of $71.29 and a 200-day simple moving average of $75.85. Spruce Biosciences has a one year low of $4.28 and a one year high of $240.00. The firm has a market cap of $68.67 million, a P/E ratio of -1.24 and a beta of 3.62.

Institutional Investors Weigh In On Spruce Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cable Car Capital LP purchased a new stake in shares of Spruce Biosciences during the third quarter worth about $239,000. SkyView Investment Advisors LLC acquired a new stake in Spruce Biosciences in the 4th quarter worth approximately $261,000. State Street Corp purchased a new stake in Spruce Biosciences during the 4th quarter worth approximately $558,000. Superstring Capital Management LP purchased a new stake in Spruce Biosciences during the 4th quarter worth approximately $1,057,000. Finally, Geode Capital Management LLC acquired a new position in Spruce Biosciences during the 4th quarter valued at approximately $1,109,000. 91.71% of the stock is currently owned by hedge funds and other institutional investors.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.